secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066374
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed reports Q1 cash $245.5M; Phase 3 trials on track for 2026 topline data
------------------------------------------------------------------------------

- Cash and investments $245.5M at March 31, 2025; runway into 2027 and at least 12 months beyond first Phase 3 readout.
- Dosed first patient in Phase 3 Emerge study of MM120 ODT for MDD; topline data expected 2H 2026.
- Enrollment on track in Phase 3 Voyage and Panorama studies for GAD; topline data 1H 2026 (Voyage) and 2H 2026 (Panorama).
- Amended K2 HealthVentures loan: up to $120M available, received ~$17.8M net cash, interest-only period extended through May 1, 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000095017025066374/0000950170-25-066374-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000095017025066374/mnmd-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066374

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer